GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sinocare Inc (SZSE:300298) » Definitions » EBIT

Sinocare (SZSE:300298) EBIT : ¥370 Mil (TTM As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Sinocare EBIT?

Sinocare's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥122 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥370 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sinocare's annualized ROC % for the quarter that ended in Mar. 2024 was 8.87%. Sinocare's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 24.06%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sinocare's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 2.31%.


Sinocare EBIT Historical Data

The historical data trend for Sinocare's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinocare EBIT Chart

Sinocare Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 305.98 260.69 165.89 559.31 314.85

Sinocare Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 66.91 145.31 170.59 -67.96 121.75

Competitive Comparison of Sinocare's EBIT

For the Medical Devices subindustry, Sinocare's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinocare's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sinocare's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sinocare's EV-to-EBIT falls into.



Sinocare EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥370 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinocare  (SZSE:300298) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sinocare's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=474.228 * ( 1 - 15.75% )/( (4465.419 + 4543.916)/ 2 )
=399.53709/4504.6675
=8.87 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5926.972 - 654.336 - ( 816.038 - max(0, 1299.124 - 2106.341+816.038))
=4465.419

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5819.717 - 603.202 - ( 672.599 - max(0, 1173.834 - 1998.458+672.599))
=4543.916

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Sinocare's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=486.992/( ( (1828.828 + max(139.068, 0)) + (1838.549 + max(241.653, 0)) )/ 2 )
=486.992/( ( 1967.896 + 2080.202 )/ 2 )
=486.992/2024.049
=24.06 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(478.22 + 632.445 + 142.069) - (654.336 + 0 + 459.33)
=139.068

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(547.319 + 622.683 + 127.794) - (603.202 + 0 + 452.941)
=241.653

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sinocare's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=369.682/15983.421
=2.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinocare EBIT Related Terms

Thank you for viewing the detailed overview of Sinocare's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinocare (SZSE:300298) Business Description

Traded in Other Exchanges
N/A
Address
No.265 Guyuan Road, Hi-tech Zone, Hunan Province, Changsha, CHN, 410205
Sinocare Inc operates in the healthcare industry. It is engaged in the development, manufacturing, and marketing of diagnosis testing products for people with chronic diseases and healthcare professionals. Its product range covers household blood glucose meter, medical blood glucose meter, urinary microalbumin test strip and blood lipid uric acid products. In addition, the company also provides diabetes management information systems.
Executives
Li Shao Bo Directors, executives
Che Hong Jing Director
Wang Shi Min Executives
Huang An Guo Directors, executives
Directors, executives
Pan Shu Guang Securities Affairs Representative
Zhou Qing Hua Supervisors
Ning Gui Chun Supervisors
Wang Rui Securities Affairs Representative
Chen Ji Dong Supervisors
Che Hong Li Directors, executives
Zhang Fan Director

Sinocare (SZSE:300298) Headlines

No Headlines